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Introduction: Adipose tissue has the unique property of expanding throughout adult life, and angiogenesis is
required for its growth. However, endothelial progenitor cells contribute minimally to neovascularization. Because
myeloid cells have proven to be angiogenic, and monocytes accumulate in expanding adipose tissue, they might
contribute to vascularization.
Methods: The stromal vascular fraction (SVF) cells from human adipose tissue were magnetically separated according
to CD45 or CD14 expression. Adipose-derived mesenchymal stromal cells (MSCs) were obtained from SVF CD45− cells.
CD14+ monocytes were isolated from peripheral blood (PB) mononuclear cells and then cultured with SVF-derived
MSCs. Freshly isolated or cultured cells were characterized with flow cytometry; the conditioned media were analyzed
for the angiogenic growth factors, angiopoietin-2 (Ang-2), vascular endothelial growth factor (VEGF), basic fibroblast
growth factor (bFGF), hepatocyte growth factor (HGF), granulocyte colony-stimulating factor (G-CSF), and granulocyte
macrophage colony-stimulating factor (GM-CSF) with Luminex Technology; their angiogenic capacity was determined
in an in vivo gelatinous protein mixture (Matrigel) plug angiogenesis assay.
Results: CD45+ hematopoietic cells within the SVF contain CD14+ cells that co-express the CD34 progenitor marker
and the endothelial cell antigens VEGF receptor 2 (VEGFR2/KDR), VEGFR1/Flt1, and Tie2. Co-culture experiments showed
that SVF-derived MSCs promoted the acquisition of KDR and Tie-2 in PB monocytes. MSCs secreted significant amounts
of Ang-2 and HGF, but minimal amounts of bFGF, G-CSF, or GM-CSF, whereas the opposite was observed for SVF
CD14+ cells.
Additionally, SVF CD14+ cells secreted significantly higher levels of VEGF and bFGF than did MSCs. Culture
supernatants of PB monocytes cultured with MSCs contained significantly higher concentrations of VEGF, HGF,
G-CSF, and GM-CSF than did the supernatants from cultures without MSCs. Quantitative analysis of angiogenesis
at 14 days after implantation demonstrated that neovascularization of the implants containing SVF CD14+ cells or
PB monocytes previously co-cultured with MSCs was 3.5 or 2 times higher than that observed in the implants
with SVF-derived MSCs. Moreover, immunofluorescence of Matrigel sections revealed that SVF CD14+ cells
differentiated into endothelial cells and contributed to vascular endothelium.
Conclusions: The results from this study suggest that adipose tissue-resident monocytes should contribute to tissue
vascularization. Because SVF CD14+ cells were more efficient in inducing angiogenesis than SVF-derived MSCs,
and differentiated into vascular endothelial cells, they may constitute a new cell source for cell-based therapeutic
angiogenesis.* Correspondence: minyana_mdo@gva.es
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Adipose tissue is composed of mature adipocytes and a
heterogeneous stromal cell population surrounding them
termed stromal vascular fraction (SVF) [1]. Adipose tissue
is highly vascularized and has the unique property
of expanding and regressing throughout adult life [2].
Although angiogenesis is required in growing adipose
tissue, [3] the mechanisms of adipose vascularization
are not fully understood. In past years, it has become
evident that in addition to endothelial cell sprouting
from preexisting blood vessels, endothelial progenitor
cells and/or myeloid cells contribute to the angiogenic
process [4,5]. However, in an in vivo adipogenesis model,
endothelial progenitor cells minimally contributed to new
vasculature, although the role of myeloid cells in adipose-
tissue angiogenesis was not investigated [6].
Adipogenesis and angiogenesis are two closely related
processes during embryogenesis and in adult life [2,7,8],
and accumulating evidence demonstrates a functional
link among endothelial cells, adipocytes, and monocytes.
Conditioned media from adipose endothelial cells increases
preadipocyte proliferation rates [9], whereas inhibition of
vascular endothelial growth factor (VEGF)-VEGF receptor
2 (VEGFR2) signaling reduces angiogenesis and inhibits
adipocyte differentiation [10]. Conditioned media from
mature adipocytes induce overexpression of the intra-
cellular adhesion molecule and platelet/endothelial cell
adhesion molecule (PECAM)-1 in adipose endothelial cells,
which in turn increases blood monocyte adhesion and
migration to/through endothelial cells [11]. Moreover,
mature adipocytes expressing monocyte chemoattractant
protein-1, interleukin-8, and leptin are directly involved in
this chemotactic effect [11]. Leptin, which is elevated in the
plasma of obese subjects [12], increases blood monocyte
adhesion and transmigration in a concentration-dependent
manner [11] and also induces angiogenesis [13].
In expanding adipose tissue, monocytes accumulate
proportional to the body mass index and adipocyte area
[11,14]; therefore, it is tempting to speculate that mono-
cytes may contribute to adipose tissue growth. Most
efforts have been directed to the study of monocytes/
macrophages in the context of obesity [14-16]; therefore,
little information exists regarding their possible angio-
genic properties.
Therefore, to address this question, we characterized
CD14+ cells contained in the SVF from human adipose
tissue and determined the ability of these tissue-resident
monocytes to induce angiogenesis in an in vivo Matrigel
plug assay. In this study, mesenchymal stromal cells
(MSCs) derived from adipose SVF, known to be angio-
genic in animal models of ischemia [17,18], the nonhe-
matopoietic CD45− cell component of the SVF, and
blood CD14+ monocytes were used as controls in these
investigations.Methods
Tissue sampling
Human adipose tissue was obtained from female patients
undergoing abdominal lipectomy at the University General
Hospital of Valencia (Table 1 summarizes the clinical and
laboratory characteristics of patients). Peripheral blood (PB)
was obtained from adult healthy donors. The study was
approved by the Clinical Research Ethics Committee of
the Valencia University General Hospital, and patients and
donors signed an informed consent.
Cell isolation and culture
Human adipose tissue SVF was obtained after enzymatic
tissue digestion with collagenase, as previously described
[19]. The SVF cells were magnetically labeled with anti-
CD45 or anti-CD14 microbeads (Miltenyi Biotec, GmbH,
Bergisch Gladbach, Germany), and cell populations were
separated by using the MACS system (Miltenyi Biotec).
Adipose-derived MSCs were obtained from the SVF
CD45− isolated cells. In brief, CD45− cells were plated
at a density of 30,000 cells/cm2 in endothelial basal
medium (EBM-2) supplemented with EGM-2MV Single-
Quots containing VEGF, basic fibroblast growth factor
(bFGF), insulin-like growth factor-1, epidermal growth
factor, and 5% FBS, (Lonza Walkersville, Inc., Walkersville,
MD, USA). After reaching 80% to 90% confluence,
adherent cells were detached by using 0.25% trypsin-
ethylenediaminetetraacetic acid (EDTA) solution (Lonza)
and reseeded at the same density. All of the studies
were performed at the end of the second passage. PB
mononuclear cells were obtained by centrifugation over
Ficoll-Paque (Stem Cell Technologies SARL, Grenoble,
France), and CD14+ monocytes were isolated by positive
selection by using anti-CD14 microbeads and the MACS
system (Miltenyi Biotec). CD14+ cells were cultured in
EGM-2MV with or without MSCs. In brief, MSCs
were resuspended in EGM-2MV to a concentration of
0.75 × 106 cells/ml and transferred to 24-well plates
(100 μl/well). After 24 hours, 0.1 × 106 monocytes (1 × 106
cells/ml) were plated into the well (full-contact) or onto
the membrane (0.4-μm pore size) of transwell cell-culture
inserts (noncontact). At the indicated time points, mono-
cytes were removed from the membrane by washing with
phosphate-buffered saline (PBS) containing 1 mM EDTA
or harvested together with MSCs by scraping and then
analyzed with flow cytometry. All of the cell cultures were
incubated at 37°C in a humidified 5% CO2 atmosphere.
Generation of cells-conditioned media
PB mononuclear cells were divided in two parts; one half
was used to isolate untouched monocytes by using an
indirect magnetic labeling (Monocyte Isolation Kit II;
Miltenyi Biotec), whereas the other half was used to
obtain monocytes by positive selection. Each of the
Table 1 Clinical characteristics of the study patients
Variables <45 years (n = 12) ≥45 years (n = 18)
Sociodemographics
Age (years) 34.7 ± 5.3 (24–39) 53.7 ± 5.1 (46–64)
White (%) 100 100
Habits
Smoking (%) 33.3 50
Alcohol consumption (%) 8.3 0
Drugs consumption (%) 0 0
Clinical characteristics
Glucemia (mg/dl) 94.75 ± 13.87 (67–108) 101.65 ± 28.50 (79–183)
Systolic BP (mm Hg) 128.33 ± 11.29 (111–138) 128.59 ± 21.72 (104–180)
Diastolic BP (mm Hg) 71.58 ± 9.10 (59–89) 70.53 ± 7.06 (58–82)
Diabetes (%) 0 16.7
Hypertension (%) 8.3 5.6
Hyperlipidemia (%) 0 5.6
Diabetes treatment (%) 0 16.7
Antihypertensive treatment (%) 8.3 5.6
Lipid-lowering treatment (%) 0 5.6
BP, blood pressure. Values are expressed as mean ± SD, or as percentages, when indicated. The range of values is given in parentheses.
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in RPMI (Lonza) with 5% autologous plasma (condition 1)
or in EBM-2 with 2.5% FBS (condition 2). Additionally,
monocytes were cultured in EGM-2MV (condition 3) or
in a transwell system with adipose-derived MSCs for
5 days. At the end of the culture period, monocytes were
switched to EBM-2 with 2.5% FBS, and 72 hours later,
conditioned media were collected. Isolated SVF CD14+
cells were divided in two parts: one was cultured as in
condition 2, and the remaining cells, as in condition 3.
Adipose-derived MSCs were grown in EGM-2MV
until confluent, and then switched to EBM-2 with 2.5%
FBS. Seventy-two hours later, conditioned media were
collected, centrifuged, and frozen at −80°C until use.
Conditioned media were analyzed for the angiogenic or
antiapoptotic growth factors, angiopoietin-2 (Ang-2),
VEGF, bFGF, granulocyte colony-stimulating factor (G-
CSF), granulocyte macrophage colony-stimulating factor
(GM-CSF), and hepatocyte growth factor (HGF) with
Luminex xMAP Technology by using a Luminex Screen-
ing Assay (R&D Systems Minneapolis, MN, USA).
Flow-cytometry analysis
Cells were stained in PBS containing 1 mM EDTA and
1% bovine serum albumin (BSA) with specific antibodies
or isotype-matched controls for 30 minutes at 4°C in the
dark. After washing, cells were analyzed on a FACSCanto
II (BD Biosciences, Erembodegem, Belgium) by using
FACSDiva software (BD Biosciences). The antibodies used
were CD9, CD13, CD14, CD31, CD34, CD45, CD144,CD146, CD90, CD105 (BD Biosciences), VEGFR1/Flt-1
(clone 49560; R&D Systems, Abingdon, UK), VEGFR2/
KDR (clone ES8-20E6 from Miltenyi Biotec and clone
89106 from R&D Systems), and Tie2/Tek (clone 83715
from R&D Systems and clone 33.1(Ab33) from BioLegend,
Uithoorn, The Netherlands) conjugated to fluorescein-
isothiocyanate (FITC), phycoerythrin (PE), allophyco-
cyanin (APC), and PE-cyanin7 (PE-Cy7) or APC-cyanin7
(APC-Cy7). 7-Amino-actinomycin D (Sigma-Aldrich,
Madrid, Spain) was used for removal of nonviable
cells in the analysis.
In vivo Matrigel plug assay
Freshly isolated SVF CD45+, CD45−, or CD14+ cells,
adipose-derived MSCs, and PB CD14+ monocytes,
freshly isolated or cocultured with MSCs in a transwell
system (1 × 106 cells in 50 μl PBS) were individually
mixed with 400 μl of growth-factor-reduced Matrigel
(BD Biosciences) and injected subcutaneously into the
dorsal flank of 8- to 12-week-old female Hsd:athymic
nude-Foxn1nu mice (Harlan Laboratories, Udine, Italy).
Matrigel with PBS alone was used as negative control.
Matrigel plugs were removed on day 14, fixed in zinc
fixative solution (BD Biosciences), and embedded in par-
affin for hematoxylin and eosin (H&E) staining or for
immunohistochemistry. For the functional perfusion of
neovessels in Matrigel, 10 minutes before the Matrigel
plugs were harvested, FITC-dextran (MW 70,000, Sigma-
Aldrich) was injected intravenously into the tail vein. The
mice were killed by intraperitoneal sodium pentobarbital
Table 2 Surface marker expression on freshly isolated
SVF cells
Cells Percentage mean ± SD
Crude SVF cells
CD45 19 ± 11 (n = 30)
CD34 48 ± 20 (n = 30)
SVF CD45− cells
CD34 70 ± 20 (n = 30)
SVF CD45+ cells
CD34 29 ± 13 (n = 30)
CD14 35 ± 13 (n = 20)
SVF CD34+ cells
CD90 90 ± 9 (n = 20)
CD13 77 ± 17 (n = 10)
CD31 22 ± 11 (n = 20)
SVF CD45+CD34+ cells
CD14 64 ± 17 (n = 12)
SVF CD45+CD14+ cells
CD34 55 ± 13 (n = 20)
CD31 66 ± 16 (n = 10)
KDR 55 ± 17 (n = 8)
Tie-2 32 ± 14 (n = 8)
Flt-1 34 ± 23 (n = 5)
Cell populations in the stromal vascular fraction were characterized with flow
cytometry. Values indicate the percentage of cells expressing selected
antigens within the SVF cell subsets. Results are expressed as mean ± SD.
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formity with institutional guidelines in compliance with
the Spanish guidelines for animal care (RD 1201/2005)
and the European Community Council Directive (2010/
63/UE), and were approved by the Council of Agriculture
of the Valencian Regional Government and by the internal
Committee for Ethics and Animal Research.
Matrigel-plug immunohistochemistry and
immunofluorescence
Matrigel plugs in 5-μm deparaffined sections were reacted
with primary rabbit polyclonal anti-human CD45 (1/1,000
dilution) or anti-endothelial nitric-oxide synthase (eNOS)
(1/100 dilution) (Abcam, Cambridge, UK), or monoclonal
rat anti-mouse CD31 (1/25 dilution, clone MEC13.3; BD
Pharmingen). For CD45 and e-NOS, antigens were heat-
retrieved in Antigen Retrieval Solution (Dako, Glostrup,
Denmark), and endogenous peroxidase activity blocked by
using 3% hydrogen peroxide in methanol. Sections were
incubated at 4°C overnight with the primary antibodies.
Nonspecific protein-binding sites and endogenous mouse
IgG were sequentially blocked by incubation in PBS
containing 0.1% Triton X-100, 0.5% BSA, and 10% fetal
bovine serum (FBS) for 1 hour at room temperature (RT)
followed by nonconjugated AffiniPure Fab Fragment goat
anti-mouse IgGs (Jackson ImmunoResearch Laboratories,
West Grove, PA, USA) for 2 hours at RT. Sections were
then incubated with biotin-conjugated secondary antibodies
and treated with streptavidin-horseradish peroxidase, and
the reaction was developed by using 3,3′-diaminobenzidine
(DAB) substrate (LSAB + System-HRP; Dako).
For CD31, after blocking of endogenous peroxidase
activity, the sections were incubated with the primary
antibody at RT for 1 hour followed by blocking of non-
specific protein and endogenous mouse IgG. Primary
antibodies were detected by sequential incubation with
biotinylated secondary antibodies, streptavidin-horseradish
peroxidase, and DAB substrate (Anti-Ig HRP Detection
Kit, BD Biosciences). All of the slides were counterstained
with hematoxylin.
For double immunofluorescence, tissue sections were
dewaxed, rehydrated, incubated in Antigen Retrieval
Solution (BD Pharmingen), permeabilized with 0.2%
Triton-X100 in PBS for 30 minutes, and blocked for
1 hour at RT with 1% BSA and 10% normal goat serum
(Jackson Immunoresearch Laboratories) in PBS. Sections
were then immunostained with rabbit anti-human von
Willebrand factor (vWF; 1/100 dilution, Sigma), rabbit
anti-human nestin (1/250 dilution, Millipore, Temecula,
CA, USA) or rabbit anti-α-smooth muscle actin (αSMA;
1/100 dilution; Abcam), overnight at 4°C, followed by goat
anti-rabbit conjugated with Alexa 555 (Jackson Immu-
noresearch Laboratories). Then, to identify murine endo-
thelial cells, slides were stained with rat anti-mouse CD31(1/25 dilution, clone MEC13.3; BD Pharmingen) followed
by goat anti-rat conjugated with Alexa 488.
To identify human endothelial cells, slides were blocked
with Carbo-Free blocking solution (Vector Laboratories,
Burlingame, CA, USA) and stained with biotinylated Ulex
europaeus agglutinin 1 (UEA-1; 1/100 dilution, Vector
Laboratories) for 1 hour at RT followed by fluorescein
(DTAF)-conjugated streptavidin (Jackson Immunoresearch
Laboratories). The αSMA and the vWF antibodies are
cross-reactive for mouse and human. Images were
acquired by using a Leica DFC480 camera and Leica
DM6000 microscope with the Leica Application Suite
(LAS), Version 3.6.0.
Neovessel quantification in Matrigel plugs
In H&E-stained sections, newly formed vessels were
defined as endothelium-lined tubular structures con-
taining clearly identifiable erythrocytes. One in every
five slides was counted, by using a 40× objective, in a
blinded fashion, and the number of vessels per square
millimeter was averaged. Five animals were used for each
condition. The lumen area was determined by using
Leica Application Suite, v4.0 software (Leica Microsystems,
Wetzlar, Germany).
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The results were expressed as the mean ± standard devi-
ation. The data were analyzed by using GraphPad Prism
Software 5.0 (GraphPad Software Inc., La Jolla, CA, USA).
The comparisons among groups were analyzed in a
one-way ANOVA followed by Bonferroni post hoc test
and, when appropriate, by Student t test. Differences were
considered to be statistically significant at P < 0.05.
Results
Hematopoietic cell population from the SVF contains CD14+
cells expressing CD34 and displaying an endothelium-like
phenotype
Human adipose tissue SVF reportedly contains a variable
proportion of CD34+ cells [1,19,20]. Here, we demonstrate
that CD34+ cells accounted for approximately 50% of SVF
cells. Most CD34+ cells expressed CD90 and CD13, which
was indicative of their mesodermal origin, and a lower
proportion were positive for CD31 (Table 2). As expected,Figure 1 SVF CD14+ cells exhibit a proangiogenic phenotype. PB nucl
right, CD34+CD45low cells corresponding to hematopoietic progenitor cells ar
CD14 expression and for co-expression of CD14 with CD31, Tie2, KDR, Flt-1, an
accounted for 98.5% of the total viable PB nucleated cells. SVF cells (B) were a
analyzed for CD34 and CD14 expression and for the co-expression of CD14 w
are shown. CD45+ cells accounted for 6% of total viable cells. Dot plots of CDCD45− cells were abundant in the SVF, and the majority
of these cells expressed CD34. Unexpectedly, we found
that approximately 30% of the remaining CD45+ hema-
topoietic cells also expressed CD34 (Table 2). In human
PB, CD34 is a marker of hematopoietic progenitors;
thus, virtually all CD34+ cells exhibit little or no CD45
expression, lack expression of cell-surface markers that
are associated with the CD45+ lineage [21] and are clus-
tered in a discrete cell population when analyzed with flow
cytometry (Figure 1A). However, approximately 65% of
CD45+CD34+ SVF cells co-expressed CD14 (Table 2;
Figure 1B). Further analysis of the CD45+ SVF cells
demonstrated that 35% of them expressed CD14, of
which 55% co-expressed CD34 (Figure 1B), whereas most
of the remaining CD45+ cells identified the lymphocyte
subset. Remarkably, most adipose CD14+ cells expressed
CD31 and exhibited an endothelium-like phenotype, in
contrast to what was observed in circulating CD14+
monocytes, as demonstrated by KDR, Tie-2, and Flt1eated cells (A) were analyzed for CD45 and CD34 expression. Top
e shown. Bottom, CD45+ cells (blue) were gated and analyzed for
d CD34. The CD14+ cells represented 20% of CD45+ cells, which in turn
nalyzed for CD45 expression, and then the gated CD45+ cells (blue) were
ith CD31, CD144, Tie2, KDR, Flt-1, and CD34. Isotype-matched controls
14 conjugated with APC or PE correspond to three different samples.
Navarro et al. Stem Cell Research & Therapy 2014, 5:50 Page 6 of 16
http://stemcellres.com/content/5/2/50co-expression (Table 2, Figure 1B), although CD144
expression was barely detected (Figure 1).
Adipose-derived MSCs promote the expression of
endothelial markers in circulating monocytes
Because adipose stromal cells secrete a wide variety of
angiogenic factors [22], circulating CD14+ monocytes
could acquire an endothelial cell phenotype after tissue
recruitment. To test this hypothesis, PB CD14+ cells
were cultured on a monolayer of adipose-derived MSCs,
and the induced phenotypic changes were evaluated. As
demonstrated in Figure 2A, SVF-derived MSCs had typ-
ical fibroblast morphology; expressed the mesodermal
antigens CD9, CD13, CD90 and CD105; and lackedFigure 2 Phenotypic characteristics of adipose-derived MSCs. CD45− S
in EGM-2 MV to generate MSCs. Morphologic aspect of MSCs at passage
demonstrating the expression of a panel of markers in MSCs are shown iexpression of CD31, CD34, VEGFR2/KDR and Tie-2
(Figure 2B). We observed that after 3 days in co-culture,
approximately 40% (range, 20% to 50%; n = 4) and 30%
(range, 10% to 40%; n = 4) of CD14+ monocytes expressed
KDR and Tie-2, respectively (Figure 3B), and these cell
proportions were maintained for the next 4 days. Of note,
a similar level of induction was observed when CD14+
monocytes were seeded into transwell membranes; thus,
direct contact between monocytes and MSCs was not
necessary to induce changes in their antigen-expression
profile. As expected, no phenotypic changes were ob-
served when CD14+ cells were cultured in endothelial
growth medium, most likely because they were cultured
on tissue-culture plastic (Figure 3B). However, CD34VF cells were isolated by immunomagnetic methods and then cultured
2 (scale bar, 100 μm) is shown in panel (A). Flow-cytometry dot plots
n (B). Isotype-matched controls are given.
Figure 3 Induction of endothelial markers in circulating CD14+ cells. CD14+ monocytes were isolated from adult PB, cultured in EGM-2 MV
with or without MSCs, and then analyzed with flow cytometry. Dot plots from freshly isolated CD14+ cells (A) and after 4 days of co-culture with
adipose-derived MSCs (green) (B) are shown. Flow-cytometry histograms in panels A and B show the expression of KDR and Tie2 in gated CD14+
cells. Isotype-matched controls are given.
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(data not shown).
SVF CD14+ cells are highly angiogenic
To determine the angiogenic capacity of hematopoietic
cells contained in the SVF, we performed subcutaneous
Matrigel implantation with SVF CD45+ cells and com-
pared the resulting angiogenesis with that obtained by
using SVF CD45− cells and SVF-derived MSCs. Two weeks
after implantation, the gross morphologic appearance of
the explanted plugs revealed the induction of angiogen-
esis in Matrigel implants containing SVF-derived cellsin contrast to the lack of angiogenesis that was observed
with Matrigel alone (Figure 4A). Macroscopically, the
neovessels induced by SVF cells were well organized
and formed a dense capillary network, and some blood
vessels with the appearance of arterioles were observed
(Figure 4B). Histologic sections demonstrated the presence
of blood vessels lined with endothelial cells of very different
sizes that contained varying amounts of erythrocytes
(Figure 4C,D). Interestingly, the number of neovessels
formed in implants containing SVF CD45+ cells was
higher (1.3-fold increase) than in those containing SVF
CD45− cells or SVF-derived MSC, which was nearly
Figure 4 Angiogenic response induced by SVF cells in the Matrigel-plug assay. Freshly isolated SVF CD45+, CD45−or CD14+ cells, or
SVF-derived MSCs were mixed with Matrigel and injected subcutaneously into immunodeficient mice. (A) Macroscopic visualization of Matrigel
plugs containing SVF cells or no cells 14 days after implantation. In some experiments, 10 minutes before the Matrigel plugs were harvested, mice
were injected into the tail vein with FITC-dextran. Fluorescence microscopy of Matrigel explants allows identifying vessels connected to the circulation
(B). Sections from the plugs were stained with H&E to visualize vessel formation (C, D). Scale bars: B, 200 μm (left), 100 μm (right); C and D, 50 μm.
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distribution were observed among vessels induced by SVF
CD45+ cells and those induced by SVF CD45− cells or
MSCs (Figure 5B). Although most Matrigel-implant neo-
vessels were small vessels with a lumen area ≤150 μm2, wealso observed the development of a few very large blood
vessels (lumen area ranging between 1,000 and 3,000 μm2).
Given the cellular composition of the SVF CD45+ cell
population, CD14+ cells must be the main cells respon-
sible for the angiogenic activity observed. When isolated
Figure 5 Quantification of neovessels in Matrigel plugs. Freshly
isolated SVF cells, SVF-derived MSCs, and PB CD14+ monocytes, freshly
isolated or after co-culture with SVF-derived MSCs in a transwell system,
were individually embedded in Matrigel at 1 × 106 cells per implant.
Matrigel explants were harvested 14 days after implantation and
H&E-stained sections were used to enumerate blood vessels (A). The
lumen area of newly formed vessels in Matrigel implants containing
SVF-derived MSCs or SVF-isolated CD45+ or CD45− cells was determined.
Vessel distribution indicates the percentage of vessels according to their
lumen area, given as range of values (B). Results are expressed as the
mean and SD of five Matrigel implants per test group. MSCs derived
from three independent SVFs were used. *P< 0.0001 for differences
between groups linked by the brackets.
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noticed; on a per-cell basis, the number of neovessels
induced by SVF CD14+ cells was approximately 3.5-foldincreased when compared with that induced by SVF-
derived MSCs (Figure 5A). Finally, we tested whether
the co-culture system led blood monocytes to increase
their angiogenic capacity. As shown in Figure 5A, the
number of neovessels in implants containing PB mono-
cytes co-cultured with SVF-derived MSCs in a transwell
system was 6 times higher than that obtained by using
PB-isolated monocytes.
SVF CD14+ cells secrete angiogenic factors
To explore further the possibility that SVF CD14+ cells
and PB monocytes that had been cultured with MSC
promoted angiogenesis in a paracrine manner, we deter-
mined the levels of the angiogenic and antiapoptotic
factors Ang-2, VEGF, bFGF, G-CSF, GM-CSF, and HGF
in the conditioned media. We found that SVF CD14+ cells
cultured in EGM-2MV secreted approximately threefold
more VEGF and up to 16-fold more bFGF than the SVF-
derived MSCs cultured in the same medium. By contrast,
a lesser secretion of Ang-2 was observed, and HGF was
minimally secreted. Importantly, when SVF CD14+ cells
were cultured in EBM-2, a medium that does not contain
angiogenic factors, the level of secretion of VEGF and
bFGF was increased approximately twofold, whereas that
of G-CSF and GM-CSF was decreased by six- and twofold,
respectively (Table 3). Next, to assess whether the type
of selection used to isolate PB monocytes had affected
their ability to secrete angiogenic factors, we obtained
conditioned media from both positive selected monocytes
and indirectly selected monocytes, termed untouched
monocytes. As seen in Table 3, no differences were found
in the secretion of growth factors studied between mono-
cytes obtained by either of the two methods, in any of the
culture media used. Nevertheless, untouched monocytes
secreted higher amounts of G-CSF, and slightly lower
levels of Ang-2, than positive selected monocytes when
cultured in EBM-2 or EGM-2MV, respectively. When
PB CD14+ cells were co-cultured with MSCs, they were
induced to secrete high levels of VEGF, and of G-CSF
and GM-CSF, reaching values similar to those observed
in SVF-derived MSCs, and SVF CD14+ cells cultured in
EGM-2MV, respectively.
SVF CD14+ cells incorporate into neovessels
Neovessel recruitment and formation into the Matrigel
plugs with SVF cells were also evaluated by staining with
anti-mouse CD31 antibody. Because nude mice were
used for in vivo angiogenesis assay, the explanted plugs
did not demonstrate inflammatory reactions, and cells
expressing CD31 must correspond to host endothelial
cells. The majority of the endothelial cells lined together
and formed blood vessels (Figure 6A). To investigate the
contribution of the SVF CD14+ cells to the establishment
of a vascular network in Matrigel plugs, sections were
Table 3 Secretion of growth factors by SVF-derived MSC, SVF CD14+ cells, and PB monocytes
Ang-2 VEGF HGF bFGF G-CSF GM-CSF
SVF-derived MSCs 1,642 ± 1,157 329 ± 69 12,602 ± 1,492 21 ± 3 70 ± 13 3.2 ± 1.2
PB-positive selected monocytes
Condition 1 200 ± 35 40 ± 5 7 ± 1 12 ± 5 0.6 ± 0.2 1.9 ± 0.2
Condition 2 186 ± 78 52 ± 25 20 ± 19 12 ± 2 7.4 ± 2.2 15 ± 4
Condition 3 278 ± 18 48 ± 15 137 ± 35 25 ± 2 3.4 ± 1.2 5 ± 2
Co-cultured with MSCs 26 ± 9* 210 ± 49 155 ± 71* 34 ± 4 4,188 ± 2,001* 957 ± 552*
PB-untouched monocytes
Condition 1 229 ± 36 46 ± 36 9 ± 1 11 ± 2 0.7 ± 0.3 1.5 ± 0.7
Condition 2 215 ± 142 54 ± 43 28 ± 23 16 ± 6 33 ± 7† 18 ± 8
Condition 3 216 ± 25† 61 ± 16 163 ± 75 18 ± 3 4.7 ± 1.4 4.3 ± 1.7
Co-cultured with MSCs 25 ± 9* 197 ± 96 134 ± 47* 27 ± 5† 4,321 ± 2,529* 878 ± 514*
SVF CD14+ cells
Condition 2 220 ± 123* 1,733 ± 193* 18 ± 8* 580 ± 199* 30,895 ± 6,699* 4,017 ± 791*
Condition 3 176 ± 96*‡ 916 ± 164*† 13 ± 4*‡ 341 ± 121*†‡ 5,555 ± 3,986*† 1,782 ± 1,001*†
Cells derived from adipose tissue or PB monocytes were cultured as described in Methods, and the 72-hours conditioned media were analyzed by Luminex Screening
Assays to determine the secretion of selected growth factors. Condition 1, RPMI with autologous plasma; condition 2, EBM-2 with FBS; and condition 3, EGM-2MV with
FBS and then switched to EBM-2 with FBS. Values are expressed as mean ± SD pg of the secreted factor normalized to 106 cells. SVF from six different donors were used
to generate MSCs. SVF CD14+ cells were isolated from the same SVF samples; PB monocytes were obtained from four different donors, and were co-cultured with MSCs
derived from four different donors. Statistical significance: SVF CD14+ cells or PB monocytes versus SVF-derived MSCs, *P < 0.0001; SVF CD14+ cells cultured in condition
2 versus SVF CD14+ cells cultured in condition 3, and PB-positive selected monocytes versus PB untouched monocytes: cultured in condition 2 or cultured in condition
3, †P < 0.0001; SVF CD14+ cells versus PB monocytes co-cultured with MSCs, ‡P < 0.0001.
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that most CD45+ cells were localized near or surround-
ing blood vessels. However, in random Matrigel-explant
sections, we noticed the presence of arterioles, as defined
by their structure (presence of smooth muscle cells within
the wall), that contained CD45+ cells adjacent to the endo-
thelium (Figures 4C and 6B).
Last, sections were stained with anti-human e-NOS
(Figure 6C). As expected, most vascular structures stained
positive for e-NOS, and the pattern of staining was similar
to that observed for CD45.
SVF CD14+ cells differentiate into endothelial cells
The better to determine the contribution of SVF CD14+
cells to Matrigel vasculature, we analyzed for expression
of Ulex europaeus-I lectin (UEA-I), which is specific for
human vascular endothelium. Immunofluorescence analysis
of consecutive Matrigel sections against mCD31 and
UEA-1 showed a virtually identical staining pattern
(Figure 7A,B). These findings demonstrate that SVF
CD14+ cells give rise to endothelial cells, but addition-
ally, that Matrigel implants were vascularized by blood
vessels formed both from host-derived endothelial cells
and from SVF CD14+ human cells. Co-staining for αSMA,
which identifies human and murine perivascular cells,
showed that vessel structures were composed of endo-
thelial cells (green) closely associated with perivascular
αSMA+ cells (red), the typical structure of mature blood
vessels. However, immunostained sections demonstratedthat Matrigel implants also contained vascular tube-
like structures composed of αSMA+ cells, but devoid
of mCD31+ or UEA-1-positive endothelial cells (Figure 7),
probably indicating the presence of immature blood
vessels, as previously reported [23].
Staining with anti-vWF to identify blood vessels of
human and murine origin, demonstrated that Matrigel
implants contained a significant number of vWF-positive
cells, which were not associated with Matrigel vasculature
(Figure 8A,B). Macrophages contribute to uptake of vWF
[24] and are recruited into Matrigel implants supple-
mented with FGF-2 [25]. Here, we used nonsupplemented
Matrigel implants and nude mice, but it is possible
that FGF secreted by SVF CD14+ cells contributes to
host-derived macrophage recruitment. Alternatively,
vWF-positive cells could also identify SVF CD14+ cells
contained in the implant.
Macrophages expressing the early pericyte marker NG2
proteoglycan have been shown to contribute to neovessel
formation [23]. Therefore, to assess whether SVF CD14+
cells displayed human pericyte markers, we performed
immunostaining of human nestin, which is expressed in
pericytes [26] and also in endothelial cells of newly
formed blood vessels [27]. Although the expression of
nestin was very weak, this was restricted to endothelial
cells (Figure 8C,D), and we did not observe nestin-
positive cells in the perivascular area. However, single
nestin-positive cells (indicated by arrow in Figure 8C)
were observed.
Figure 6 SVF CD14+ cells incorporate into new vessels. Fourteen days after implantation, Matrigel implants containing SVF CD14+ cells were
evaluated for the expression of CD31, CD45, and e-NOS. (A) Representative images for CD31 staining. Arrows indicate the presence of CD31+ endothelial
cells in the vessels formed. (B) Human CD45 immunostaining. Note that CD45+ cells are located surrounding blood vessels (left) or adjacent to the
endothelium (right). (C) Human e-NOS immunostaining. Arrows indicate positive staining of some blood vessels for e-NOS. Scale bars: A, 50 μm; B,
50 μm (left), 30 μm (right); C, 50 μm.
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Adipose tissue, similar to bone marrow, contains stromal
cells that secrete multiple angiogenic factors [22], and
delivery of these cells has angiogenic therapeutic poten-
tial [28]. Herein we demonstrated that the hematopoietic
cell population contained in the SVF is highly enriched
in CD45+CD14+ cells expressing CD34 antigen and an
endothelium-like phenotype. Because CD34 is lost during
leukocyte maturation, these CD14+CD34+ cells must
represent a population of immature monocytes. Simi-
larly, several groups have demonstrated the existence
of a small subset of circulating CD14+ monocytes that
exhibit stem/progenitor cell properties. Kuwana et al. [29]
cultured CD14+ cells on fibronectin without angiogenic
factors and identified a population of CD14+CD45+CD34+
monocytes with fibroblast-like morphology and the abilityto differentiate into several mesodermal lineages. Kuwana
et al. then demonstrated downregulation of CD14 and
CD45 in this specific subset of monocytes when cultured
in endothelial media; differentiation into endothelial cells
expressing CD31, CD144, VEGFR1, VEGFR2, Tie-2, von
Willebrand factor, e-NOS, and CD146; and vasculogenic
properties in vivo [30]. Conversely, by using a highly sensi-
tive antibody-conjugated magnetofluorescent liposomal
technique, Romagnani et al. [31] demonstrated that a vari-
able CD14+ cell proportion coexpressed CD34. These
CD14+CD34low cells, in contrast to fully differentiated
CD14+CD34− monocytes, exhibited high expression of
the embryonic stem cell markers Nanog and Oct-4 and
proliferated in the presence of early-acting hematopoietic
cytokines. Because CD14+CD34low staining identified
the majority of circulating KDR+ cells that differentiated
Figure 7 Matrigel implants contain blood vessels comprising human and mouse endothelial cells. Consecutive sections of Matrigel
implants with SVF CD14+ cells were double-immunostained with antibodies against mCD31 (green) and αSMA (red) (A), or Ulex europaeus agglu-
tinin 1 (UEA-1; green) and αSMA (red) (B). The images on the top of the panels A and B show merged images and correspond to the same
microscopic field at different magnifications: left, low magnification; middle, medium magnification; right, higher magnification. Images on the
bottom (A, B) show green and red fluorescence and correspond to the merged image at the highest magnification. Images in panel B corres-
pond to a consecutive section. The insets in A and B (upper left) show the field at low magnification and asterisks illustrate benchmarks. Note
that the green staining associated with murine (A) or human (B) endothelial cells in the adjacent sections is near identical. Double labeling shows
a close assembly of αSMA-positive cells to the blood vessels. White arrows indicate αSMA-positive cells lining vascular-like structures which do
not express murine (A) or human (B) endothelial cells. Scale bars in A, B (upper left): 200 μm, upper in the middle: 100 μm; upper right and
bottom: 50 μm.
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main source of PB-derived endothelial cells. However,
CD45+CD34+ cells in human ovarian tumors reportedly
share monocyte and endothelial cell phenotypic character-
istics and also have the ability to generate blood vessels
in vivo [32].
Our results show that SVF CD14+ cells induced a robust
angiogenesis in vivo in the murine Matrigel plug assays,
significantly higher than that induced by SVF-derived
MSCs, and more important, they differentiated into
fully functional endothelial cells, thereby contributing toMatrigel vasculature. Blood monocytes exit the circulation
at a low frequency, migrate between vascular endothelial
cells, and enter tissues. Among the several molecules
involved in this process, PECAM-1/CD31 can drive the
transmigration of a small subset of immature CD14+CD34+
monocytes by creating a haptotactic gradient [33] in
the absence of chemokines [34]. Therefore, the physio-
logical characteristics of adipose tissue [11] could favor
recruitment of CD14+CD34+ monocytes, which are mo-
dulated toward an endothelium-like phenotype because
they are in a highly angiogenic microenvironment [3,22].
Figure 8 Immunofluorescence detection of nestin in Matrigel implants. Representative images of consecutive sections of Matrigel implants
with SVF CD14+ cells stained by anti-mouse CD31 (green) and anti-vWF (red) (A), and by UEA-1 (green) and anti-vWF (red) (B). The arrows show
colocalization of vWF-positive cells and endothelial cells of murine or human origin. However, in Matrigel implants, other vWF-positive cells not
associated with blood vessels are shown. Double-immunofluorescence staining of human nestin (red) and mCD31 (green) (C), and human nestin
(red) and UEA-1 (green) (D). In Matrigel implants, nestin was expressed in human and murine endothelial cells, although some nestin-positive
cells (arrow) lacking mCD31 were observed. Scale bar, 50 μm.
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circulating PB monocytes, together with SVF-derived
MSCs, showed that MSCs promoted the acquisition of
the endothelial markers KDR and Tie-2 in monocytes.
But, importantly, these endothelium-like monocytes
were highly angiogenic, and so the number of neovessels
formed in implants containing these “transformed”
monocytes was significantly increased when compared
with those containing isolated PB monocytes or SVF-
derived MSCs by approximately 6 or 2 times, respectively.
Since Asahara et al. [35] described the presence of cir-
culating endothelial progenitor cells, many efforts have
been devoted to identify and characterize these cells
because they represent a potential therapeutic option
for improving neovascularization [36]. However, manyreports have indicated that these bone marrow-derived
cells are mostly of myeloid origin [37]. Furthermore,
in blood, VEGFR2 and/or Tie2 expression was mainly
restricted to monocytes, and only cells expressing either
of these antigens contributed to endothelialization of
balloon-injured femoral arteries in mice [38]. It was
recently demonstrated that common myeloid and granulo-
cyte progenitor populations also have angiogenic properties
[39]. Myeloid cells participate in physiological angiogenesis
and in pathological processes [38,40-42], and in the cancer
field, different myeloid cell populations have been shown to
regulate tumor angiogenesis [43].
Although controversy still exists regarding whether mye-
loid cells are incorporated into newly formed vessels,
elegant experiments by Grunewald et al. [44] demonstrated
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specific organs, and once retained in the perivasculature,
these cells induced in situ proliferation of resident endothe-
lial cells through a repertoire of angiogenic activity.
Among the growth factors and cytokines with angiogenic
activity, much attention has been paid to angiogenesis
induced by VEGF and bFGF [23]. Results reported here
show that these two angiogenic factors were highly
secreted by SVF CD14+ cells, even in amounts signifi-
cantly greater than those secreted by MSCs. Because HGF
was highly secreted by MSCs, unlike what was observed
in SVF CD14+ cells, HGF must play an important role
in angiogenesis induced by MSCs. Although unanimity
occurs on the angiogenic properties of G-CSF [45], some
controversy exists about whether GM-CSF induces or
inhibits angiogenesis [46]. However, when GM-CSF was
administered together with G-CSF, angiogenesis was in-
creased [47]. Therefore, it is possible that the secretion
of G-CSF and GM-CSF by SVF CD14+ cells stimulates
Matrigel angiogenesis.
Moreover, it was recently reported that Ang-2, a
regulator of vessel maturation [48], can function as a
vessel-destabilizing or as a proangiogenic molecule in
endothelial cells, depending on whether endothelial cells
express Tie2 or not [49]. However, from the experiments
performed in this work, it is difficult to establish the role
of Ang-2 in this in vivo angiogenesis assay.
Overall, our results show that SVF CD14+ cells differ-
entiated into fully functional vascular endothelial cells,
and promoted angiogenesis through a paracrine manner,
suggesting that tissue-resident CD14+ monocytes must
contribute to adipose tissue angiogenesis. Moreover, the
results highlight the role of stroma in modulating the
angiogenic capacity of monocytes recruited. Indeed, MSCs,
in a paracrine manner, induced changes in both antigen
expression and secretion ability of growth factors in PB
monocytes, which could explain their higher angiogenic
capacity.
SVF from human adipose tissue has emerged as a source
of MSCs for regenerative medicine [40,50]. However, we
show, as proof of concept, that angiogenesis induced
by SVF CD14+ cells is superior to that induced by
SVF-derived MSCs. We think these findings are rele-
vant for novel angiogenic therapies based on the use
of SVF CD14+ cells.
Conclusions
The results from this study demonstrate that SVF from
human adipose tissue contains CD14+ cells expressing
CD34, CD31, KDR, Tie-2, and Flt-1. In the Matrigel-plug
assay, these endothelium-like CD14+ cells secreted high
amounts of angiogenic factors, induced angiogenesis more
efficiently than SVF-derived MSCs, differentiated into
endothelial cells, and contributed to Matrigel vasculature.Although angiogenesis is required in growing adipose
tissue [9], the mechanisms of adipose tissue vascular-
ization are not fully understood. The present data provide
evidence that adipose tissue-resident monocytes might
contribute to new vasculature. MSCs from adipose tissue
are gaining interest for angiogenic therapies, as these
cells are easily isolated. Our findings suggest that CD14+
cells isolated from the SVF may augment the efficacy of
therapeutic angiogenesis induced by SVF-derived MSCs,
and could potentially be used alone to promote tissue
vascularization.
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